• Corpus ID: 55781630

Rupatadine: a novel second-generation antihistamine

  title={Rupatadine: a novel second-generation antihistamine},
  author={Iwona Grzelewska-Rzymowska},
Histamine is the primary mediator involved in the pathogenesis of allergic rhinitis and chronic idiopathic urticaria. Platelet-activating factor (PAF) is also a mediator which plays a key role in the allergic reaction. Rupatadine is a novel antihistamine of the second generation approved recently in Europe for the treatment of allergic rhinitis and chronic idiopathic urticaria in patients aged ≥ 12 years. Rupatadine shows both antihistamine and anti-PAF effects because it presents hybrid… 

Tables from this paper

Cardiovascular safety of antihistamines

The cardiotoxic effects of the two withdrawn drugs, terfenadine and astemizole, were manifested by prolonged QT intervals and triggering torsades de pointes (TdP) caused by blockade of the ‘rapid’ IKr potassium channels.

The benefit of H2 receptors antagonist Rupatadine in treatment for urticaria

Due to its double action, Rupatadine used perorally in the dose of 10 mg once a day is an efficient drug for treatment of urticaria, and its safety was confirmed by clinical trials.

Autoimmune urticaria

Interestingly, patients suffering from chronic spontaneous urticaria with a positive result of ASST present with longer duration and more severe course of the disease and higher requirements for antihistamines and/or alternative methods of treatment.



Rupatadine: a review of its use in the management of allergic disorders.

The introduction of rupatadine extends the range of oral agents available for the treatment of allergic disorders, including allergic rhinitis and CIU, and is as well tolerated as other commonly used second-generation H(1)-receptor antagonists.

Inhibition of eosinophil chemotaxis by a new antiallergic compound (cetirizine).

It is confirmed that cetirizine, at therapeutical concentration, has a potent inhibitory action on eosinophil response to different chemoattractant mediators such as platelet-activating factor (PAF acether) and N-formyl methionyl leucyl phenyl alanyl in vitro.

Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis.

Newly published data on its efficacy and safety suggest that this compound may improve the nasal and non-nasal symptoms in comparison to other currently available second generation H1 receptor antihistamines.

Central and Peripheral Evaluation of Rupatadine, a New Antihistamine/Platelet-Activating Factor Antagonist, at Different Doses in Healthy Volunteers

RU presents a potent dose-dependent peripheral anti-H1 activity, displaying psychomotor impairment activity only at the highest dose (80 mg), while therapeutically relevant lower doses (10 and 20 mg) were similar to placebo.

Inhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced by Ascaris suum in hypersensitive dogs

Rupatadine is effective in controlling inflammatory reactions in dog skin and the effect may be partly due to its modulation of mast cell degranulation, but not to its PAF‐antagonist properties.

Inhibitory effect of the H1 antagonist loratadine on histamine release from human basophils.

Results indicate that loratadine, in addition to H1 receptor blocking activity, has the capacity to inhibit histamine release from human basophils.

Dual effect of a new compound, rupatadine, on edema induced by platelet‐activating factor and histamine in dogs: Comparison with antihistamines and PAF antagonists

The histamine‐and PAF‐induced wheal model in dogs proved useful for independent evaluation of histamine and PAF antagonist properties of the tested compounds, as pure antagonists blocked the effect of only one of the mediators.

Rupatadine: pharmacological profile and its use in the treatment of allergic disorders

  • C. Picado
  • Medicine, Biology
    Expert opinion on pharmacotherapy
  • 2006
Rupatadine is a once-daily, non-sedating, selective and long-acting new drug with a strong antagonist activity towards both histamine H1 receptors and platelet-activating factor receptors. The use of

Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber.

  • P. StuebnerF. Horak I. Izquierdo
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2006